61755-005 NDC - EYLEA (AFLIBERCEPT)

Drug Information

Product NDC: 61755-005

Proprietary Name: EYLEA

Non Proprietary Name: aflibercept

Active Ingredient(s):
  • 40 mg/mL AFLIBERCEPT


Administration Route(s): INTRAVITREAL

Dosage Form(s): INJECTION, SOLUTION

Pharmacy Class(es):
  • Vascular Endothelial Growth Factor Inhibitor [EPC];
  • Vascular Endothelial Growth Factor Inhibitors [MoA]

Labeler Information

Labeler Name: Regeneron Pharmaceuticals, Inc.
Product Type: HUMAN PRESCRIPTION DRUG
FDA Application Number: BLA125387
Marketing Category: BLA
Start Marketing Date:11/21/2011

Package Information

No. Package Code Package Description Billing Unit
161755-005-011 SYRINGE, GLASS in 1 CARTON (61755-005-01) > .05 mL in 1 SYRINGE, GLASSML
261755-005-021 VIAL, SINGLE-USE in 1 CARTON (61755-005-02) > .05 mL in 1 VIAL, SINGLE-USEML
361755-005-541 SYRINGE, GLASS in 1 CARTON (61755-005-54) > .05 mL in 1 SYRINGE, GLASS
461755-005-551 VIAL, SINGLE-USE in 1 CARTON (61755-005-55) > .05 mL in 1 VIAL, SINGLE-USEML

NDC Record

Field Name Field Value Definition
PRODUCT NDC61755-005The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN PRESCRIPTION DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMEEYLEAThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEafliberceptThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMEINJECTION, SOLUTIONThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEINTRAVITREALThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE11/21/2011This is the date that the labeler indicates was the start of its marketing of the drug product.
MARKETING CATEGORY NAMEBLAProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
APPLICATION NUMBERBLA125387This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
LABELER NAMERegeneron Pharmaceuticals, Inc.Name of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMEAFLIBERCEPTThis is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
ACTIVE NUMERATOR STRENGTH40 
ACTIVE INGRED UNITmg/mL 
PHARM CLASSESVascular Endothelial Growth Factor Inhibitor [EPC],Vascular Endothelial Growth Factor Inhibitors [MoA] 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 2/19/2021